Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Tissue Engineering & Bioprinting: Research to Commercialization

George Truskey's Biography



George Truskey, R. Eugene and Susie E. Goodson Professor of Biomedical Engineering, Duke University

George Truskey is the R. Eugene and Susie E. Goodson Professor and Senior Associate Dean for Research in the Pratt School of Engineering. Dr. Truskey's research interests include cardiovascular tissue engineering, microphysiological systems, and the mechanisms of atherogenesis. He also studies cell adhesion and cell biomechanics, for which he focuses upon the effect of flow on endothelial cell adhesion to synthetic surfaces and monocyte adhesion to endothelium. He received a PhD degree in 1985 from MIT. He has been a faculty member in the Department of Biomedical Engineering at Duke since 1987. From 2003-2011, he was Chair of the Department of Biomedical Engineering at Duke University. He is the author of over 110 peer-reviewed research publications, a biomedical engineering textbook entitled Transport Phenomena in Biological Systems, six book chapters, over 180 research abstracts and presentations, 1 patent and 2 patent applications. He is a Fellow of the Biomedical Engineering Society (BMES), the American Institute of Medical and Biological Engineering, and the American Heart Association. He was president of BMES from 2008 to 2010. He received the Capers and Marion McDonald Award for Excellence in Mentoring and Advising from the Pratt School of Engineering at Duke (2007) and the BMES Distinguished Service Award (2012).

George Truskey Image

Human Microphysiological Systems of Blood Vessels and Skeletal Muscle for Drug Toxicity

Tuesday, 10 February 2015 at 11:30

Add to Calendar ▼2015-02-10 17:30:002015-02-10 18:30:00Europe/LondonHuman Microphysiological Systems of Blood Vessels and Skeletal Muscle for Drug ToxicityTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com

Skeletal muscle is important for drug and toxicity testing given the relative size of the muscle mass and cardiac output that passes through muscle beds, the key role of muscle in energy substrate metabolism and diabetes, its role in mediating the severity of peripheral arterial disease and heart failure, and the need for therapies for muscle diseases such as muscular dystrophy and sarcopenia. To develop a system for functional and drug testing under physiological conditions, we developed three-dimensional skeletal muscle cultures and tissue engineered blood vessels (TEBV) with a functional endothelial layer. TEBVs are of arteriolar dimensions (inner diameters between 400 µm and 800 µm) and vasoconstriction induced by 1 µM phenylephrine was stable over 5 weeks of culture. TEBVs relaxed in the presence of acetylcholine only when endothelial cells were present, consistent with their role in vascular function. The TEBV exhibited responses to inflammatory stimuli suggesting injury and repair.  Human engineered muscle bundles exhibited contraction after electrical stimulation and tetanus at high frequency of stimulation. HuMB routinely achieve twitch and tetanic contractile forces > 0.5 mN and1 mN, respectively and exhibit typical Frank-Starling like twitch force-length relationship and passive tension-length relationship.  Both TEBV and HuMB exhibited responses to Drugs similar to those observed in vivo. Supported by UH2/UH3TR000505 and the NIH Common Fund for the Microphysiological Systems Initiative.


Add to Calendar ▼2015-02-09 00:00:002015-02-10 00:00:00Europe/LondonTissue Engineering and Bioprinting: Research to CommercializationTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston, USASELECTBIOenquiries@selectbiosciences.com